Treatment Duration and Drug Regimen Correlation with Side Effects Incidence in Drug-Resistant Tuberculosis (DR-TB) Patients at Pulmonary Hospital

Article Sidebar

PDF
Published: Dec 29, 2023
DOI: https://doi.org/10.25077/jsfk.10.3.320-326.2023
Keywords:
DR-TB patients, anti-tuberculosis drugs , side e ffects incidence, tr eatment duration, drug r egimen

Main Article Content

Lusi Indriani
Department of Pharmacy, Faculty of Mathematics and Natural Science and Medical, University of Muhammadiyah Riau, Pekanbaru, Indonesia
Gita Iftitah Renitia
Department of Pharmacy, Faculty of Mathematics and Natural Science, University of Pakuan, Bogor, Indonesia
Lusi Agus Setiani
Department of Pharmacy, Faculty of Mathematics and Natural Science, University of Pakuan, Bogor, Indonesia

Abstract

The bacteria Mycobacterium tuberculosis causes Drug-Resistant Tuberculosis (DR-TB). Excessive use of drugs can
result in drug resistance with various side effects. This study aimed to analyze the correlation between the treatment duration and drug regimen with the side effects incidence in DR-TB Patients at Pulmonary Hospital Dr. M. Goenawan Partoidigdo (RSPG) Bogor. This is an observational study with a cross-sectional design. Subjects were selected with purposive sampling methods based on inclusion and exclusion criteria. The research showed that DR-TB patients were mostly male (50.2%) with productive age (46.1%). The most common DR-TB treatment experienced by patients in the advanced phase, generally for 9-24 months (75.3%), and the type of drug side effect most experienced was gastrointestinal disorders, that is nausea (55.1%). The use of standard conventional drug regimens mostly in Z, E, Eto, Km, Lfx, Cs (Pyrazinamide, Ethambutol, Ethionamide, Kanamycin, Levofloxacin, Cycloserine) of 51.4%. The chi-square analysis showed no significant correlation between the treatment duration and the incidence of side effects. At the same time, there was a meaningful correlation between the drug regimen (short-term, long-term, and conventional standard regimen) and the side effects incidence. The suspected drugs causing gastrointestinal side effects were pyrazinamide, ethambutol, ethionamide, and levofloxacin. The side effects of arthritic arthralgia were suspected to be caused by pyrazinamide, ethionamide, and levofloxacin.

Article Details

How to Cite
Indriani, L., Renitia, G. I., & Setiani, L. A. (2023). Treatment Duration and Drug Regimen Correlation with Side Effects Incidence in Drug-Resistant Tuberculosis (DR-TB) Patients at Pulmonary Hospital. Jurnal Sains Farmasi & Klinis, 10(3), 320–326. https://doi.org/10.25077/jsfk.10.3.320-326.2023
Issue
Vol. 10 No. 3 (2023): J Sains Farm Klin 10(3), Desember 2023
Section
Research Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.

References

. Riskesdas, “Laporan Riskesdas 2018 Kementrian Kesehatan Republik Indonesia,†Laporan Nasional Riskesdas 2018, vol. 53, no. 9. pp. 154–165, 2018. [Online]. Available: https://www.yankes.kemkes.go.id/assets/downloads/PMK No. 57 Tahun 2013 tentang PTRM.pdf

. Dinas Kesehatan Jabar, “Profil Kesehatan Jabar,†Dinas Kesehat., vol. 5, no. 3, pp. 248–253, 2020.

. Kemenkes, Temukan TB Obati Sampai Sembuh Penatalaksanaan Tuberkulosis Resisten Obat di Indonesia. 2020.

. Reviono, P. Kusnanto, V. Eko, H. Pakiding, and D. Nurwidiasih, “Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis,†Maj. Kedokt. Bandung, vol. 46, no. 4, pp. 189–196, 2014.

. T. G. Bawonte, C. D. Mambo, and A. S. R. Masengi, “Faktor-Faktor Yang Mempengaruhi Tuberculosis Multidrug Resistance (TB MDR),†J. e-Biomedik, vol. 9, no. 1, pp. 117–125, 2021, doi: 10.35790/ebm.v9i1.31949.

. F. R. S. Imam, J. M. L. Umboh, and J. S. B. Tuda, “Faktor-faktor Risiko yang Berhubungan dengan Kejadian Multidrug-Resistant Tuberculosis (TB-MDR) di Kota Ternate, Maluku Utara,†e-CliniC, vol. 11, no. 3, pp. 260–268, 2023, doi: 10.35790/ecl.v11i3.44459.

. World Health Organization, Consolidated Operational Guidelines on Handbook Tuberculosis. 2020.

. E. Bijawati, M. Amansyah, and Nurbiah, “The Risk Factors for Treatment of Multidrug Resistance Tuberculosis (MDR-TB) Patients in Labuang Baji General Hospital Makassar in 2017,†J. Nas. Ilmu Kesehat., vol. 1, pp. 1–17, 2018, [Online]. Available: https://journal.unhas.ac.id/index.php/jnik/article/view/4282

. M. Cutfield, T., Mowlem, L., Paynter, J., Christmas, T., Harrison, A., Lewis, C., Newton, S., & Nisbet, “Treatment and outcomes of multidrug-resistant tuberculosis in Auckland, 1995-2018. Internal medicine journal, 52(8), 1381–1386.,†Intern. Med. J., vol. 52, no. 8, pp. 1381–1386, 2022, doi: https://doi.org/10.1111/imj.15341.

. D. V. Parums, “Editorial: Updates from the world health organization (who) on global treatment recommendations for drug-susceptible and multidrug-resistant tuberculosis,†Med. Sci. Monit., vol. 27, pp. 1–3, 2021, doi: 10.12659/MSM.934292.

. M. Gupta, P. Ish, and N. Malhotra, “Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis,†Indian J. Tuberc., vol. 69, no. 3, pp. 264–267, 2022, doi: 10.1016/j.ijtb.2021.08.013.

. D. S. Budnitz, N. Shehab, M. C. Lovegrove, A. I. Geller, J. N. Lind, and D. A. Pollock, “US Emergency Department Visits Attributed to Medication Harms, 2017-2019,†JAMA - J. Am. Med. Assoc., vol. 326, no. 13, pp. 1299–1309, 2021, doi: 10.1001/jama.2021.13844.

. World Health Organization, Global Report of Tuberculosis 2018, vol. 1. 2018.

. N. Pratiwi, S. Yowani, and I. Sajinadiyasa, “Hubungan Lama Penggunaan Obat Anti Tuberkulosis Dengan Efek Samping Pada Pasien Tb Mdr Rawat Jalan Di Rsup Sanglah Denpasar,†Arch. Community Heal., vol. 3, no. 2, pp. 39–48, 2016.

. G. C. Mohapatra, M. J. Khan, and S. Nayak, “Incidence of Hyperuricemia and Gouty Arthritis in Patients Taking Pyrazinamide for the Treatment of Tuberculosis,†vol. 25, no. 6, pp. 324–328, 2021.

. R. Prasad, A. Singh, and N. Gupta, “Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis,†Ann. Natl. Acad. Med. Sci., vol. 57, no. 01, pp. 15–35, 2021, doi: 10.1055/s-0040-1722535.

. C. Y. Van Deun, A., Decroo, T., Tahseen, S., Trébucq, A., Schwoebel, V., Ortuno-Gutierrez, N., de Jong, B. C., Rieder, H. L., Piubello, A., & Chiang, “World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.,†Int. J. Antimicrob. Agents, vol. 55, no. 1, 2020, doi: https://doi.org/10.1016/j.ijantimicag.2019.10.003.

. M. Dalcolmo et al., “Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: A nationwide report from Brazil,†Eur. Respir. J., vol. 49, no. 3, pp. 9–13, 2017, doi: 10.1183/13993003.02445-2016.

. A. Javaid, N. Ahmad, A. H. Khan, and Z. Shaheen, “Applicability of the World Health organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country,†Eur. Respir. J., vol. 49, no. 1, 2017, doi: 10.1183/13993003.01967-2016.

. N. D. P. Septyani and F. Lestari, “Efektivitas Penggunaan Obat Antituberkulosis ( Oat ) Lini Kedua Pada Pasien Multidrug Resistant Tuberculosis ( Mdr-Tb ) di Indonesia,†Univ. Islam Bandung, vol. 6, no. 2, pp. 1–8, 2018.

. N. B. Ngoc et al., “Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam,†PLoS One, vol. 16, no. 9 September, pp. 1–13, 2021, doi: 10.1371/journal.pone.0255357.